Identification of CD39 as a Marker for the Circulating Malignant T-Cell Clone of Sézary Syndrome Patients

J Invest Dermatol. 2019 Mar;139(3):725-728. doi: 10.1016/j.jid.2018.09.026. Epub 2018 Oct 25.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD / immunology
  • Antigens, CD / metabolism*
  • Apyrase / immunology
  • Apyrase / metabolism*
  • Biomarkers, Tumor / blood*
  • Biopsy, Needle
  • Case-Control Studies
  • Flow Cytometry
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Neoplastic Cells, Circulating / pathology
  • Prognosis
  • Reference Values
  • Sezary Syndrome / immunology
  • Sezary Syndrome / pathology*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology*
  • T-Lymphocytes / immunology
  • Tumor Burden / immunology

Substances

  • Antigens, CD
  • Biomarkers, Tumor
  • Apyrase
  • CD39 antigen